The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr.
MECHANISM OF ACTION
Ado-trastuzumab emtansine is a conjugate of trastuzumab with a cytotoxic (DM1) moiety. The conjugate combines the antibody-dependent cellular cytotoxicity of trastuzumab with the cytotoxic effect of DM1. DM1 functions as an antimitotic agent similar to the vinca alkaloids. [3] [4] [5] 
PHARMACOKINETICS
At the recommended dose of 3.6 mg/kg every 3 weeks, the maximum serum concentration (C max ) is 74.3 6 20.1 mcg/kg, the area under the time versus concentration curve (AUC) is 295.2 6 65.4 mcg•d/mL, the terminal half-life (T 1 2 ) is 3.5 6 0.8 days, and the volume of distribution (V d ) is 60 6 13.6 mL/kg. 5 At 2.4 mg/kg weekly, C max is 54. 8 6 12.6 mcg/kg, AUC is 198.5 6 54.5 mcg•d/mL, T 1 2 is 3.4 6 1.1 days, and the V d is 55.4 6 13 mL/kg. 6 The manufacturer reports C max of the ado-trastuzumab conjugate and the DM1 component as 83. 4 
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Edema (peripheral) (all grades) 4% to 10% 5, 11 ; hypertension (all grades) 4% 5 ; hypotension (all grades) 4%. 5 B. Central Nervous System: Depression (all grades) 10%, 9 (grade 1) 5%, 9 (grade 2) 3%, 9 (grade 3) 3% 9 ; dizziness (all grades) 4% 5 ; headache (all grades) 8% to 41%, 5, 6, 8, 9, 11 (grade 1) 18%, 9 (grade 1 or 2) 40%, 8 (grade 2) 4%. 9 C. Constitutional: Abdominal pain (all grades) 8% to 9%, 5,9 (grade 1) 6%, 9 (grade 2) 2%, 9 (grade 3) 1%, 9 (grade 4) 1% 9 ; arthralgia (all grades) 8% to 23%, 5, 6, 8, 9, 11 (grade 1) 10%, 9 (grade 1 or 2) 21%, 8 (grade 2) 3%, 9 (grade 3) 1% to 2% 8, 9 ; back pain (all grades) 18% to %, 9, 11 (grade 1) 12%, 9 (grade 2) 4%, 9 (grade 3) 3%, 9 ($grade 3) 1% 11 ; chills (all grades) 4% to 11% 5, 6 ; fatigue (all grades) 35% to 65%%, 5,6,8-11 (grade 1) 30%, 9 (grade 1 or 2) 61%, 8 (grade 2) 27%, 9 (grade 3) 5% to 7%, 6, 8, 9 ($grade 3) 2% to 4% 10, 11 ; infusion reactions (all grades) 4% to 1%, 5,9 (grade 1) 8%, 9 (grade 2) 6% 9 ;
muscle spasms (all grades) 8% to 11%, 5,9 (grade 1) 8%, 9 (grade 2) 3% 9 ; myalgia (all grades) 8% to 14% 5, 9 ; (grade 1) 13%, 9 (grade 2) 1%, 9 pain in extremity (all grades) 14% to 22%, 8, 9 (grade 1) 10%, 9 (grade 1 or 2) 22%, 8 (grade 2) 2%, 9 (grade 3) 2% 9 ; pyrexia (all grades) 8% to 41% 5, 6, 8, 9, 11 ; (grade 1) 14%, 9 (grade 1 or 2) 34%, 8 (grade 2) 8%, 9 (grade 3) 1% 8, 9 ; tumor pain (all grades) 4% 5 ; weight loss (all grades) 11%, 9 (grade 1) 7%, 9 (grade 2) 3%, 9 (grade 3) 1%. 9 D. Dermatologic: Alopecia (all grades) 4% 11 ; onychoclasis (all grades) 4%. 5 E. Electrolyte/endocrine abnormalities: Hyperglycemia (all grades) 7%, 9 (grade 1) 5%, 9 (grade 3) 3% 9 ; hypocalcemia (all grades) 4% 5 ; hypokalemia (all grades) 4% to 24%, 5,8-10 (grade 1) 19%, 9 (grade 1 or 2) 15%, 8 (grade 2) 1%, 9 (grade 3) 1% to 9%, 8, 9 ($grade 3) 2% 10 ; hypomagnesemia (all grades) 4%. 5 F. Gastrointestinal: Anorexia (all grades) 13% to 21%% 5,6,9 ; (grade 1) 13%, 9 (grade 2) 7%, 9 (grade 3) 1% 9 ; constipation (all grades) 8% to 30% 5,6,8,9 ; (grade 1) 20%, 9 (grade 1 or 2) 30%, 8 (grade 2) 3%, 9 (grade 3) 1% 9 ; diarrhea (all grades) 13% to 26%, 6,8-11 (grade 1) 9%, 9 (grade 1 or 2) 26%, 8 (grade 2) 9%, 9 ($grade 3) 2% 10 ; dry mouth (all grades) 4% to 32% 5,6,9 ; (grade 1) 17%, 9 (grade 2) 3% 9 ; dysgeusia (all grades) 4% to 11% 5,6 ; dysphonia (all grades) 4% 5 ; mucosal inflammation (all grades) 4% to 7% 5,10 ; ($grade 3) 0.2% 10 ; nausea (all grades) 25% to 51%% 5,6,8-11 ; (grade 1) 26%, 9 (grades 1 or 2) 50%, 8 10, 11 ; epistaxis (all grades) 13% to 36% 5, 6, 8, 9, 11 ; (grade 1) 19%, 9 (grade 1 or 2) 34%, 8 (grade 2) 3%, 9 (grade 3) 1% to 2% 8, 9 ; leukopenia (all grades) 8% to 24%, 5,6,11 ($grade 3) 2% to 
MECHANISM OF ACTION
Radium-223 dichloride emits alpha particles that cause double-strand DNA breaks, which the cell is incapable of repairing. [12] [13] [14] Radium is reported to selectively incorporate into bone at regions of active bone turnover, maximizing the radiation dose given locally and reducing the effects on normal tissue. [15] [16] [17] [18] [19] 
PHARMACOKINETICS
Radium-223 dichloride is 61% distributed to bone within 4 hours. The drug is excreted fecally (13%) and renally (2%) within 48 hours. Sixty-three percent of a dose is excreted within 7 days. 19 Selected therapeutic regimens of radium-223 dichloride appear in Table 2 .
PREPARATION
1. Follow institutional policies for preparation of radioisotopes and hazardous medications when preparing radium-223 dichloride. 2. Use radium-223 dichloride injection, 27 mCi/mL (at the reference date). 3. Dispense in a syringe.
ADMINISTRATION
Radium-223 dichloride is administered as a slow IV injection over 1 minute.
TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Chest pain 3% 21 ; dehydration (severe) 3% 21 ; myocardial infarction (severe) 3%. 21 B. Central Nervous System: Confusion (mild) 3%. 21 C. Gastrointestinal: Constipation (mild) 18%, 21 (moderate) 15%, 21 21 (severe) 3% 21 ; pseudomonas (severe) 3% 21 ; sepsis (severe) 3%. 21 F. Metabolic: Bone pain (mild) 6%, 21 (moderate) 21%, 21 (severe) 3% 21 ; bone pain/ ''flare'' 36%, 20 fatigue 20% 20 ; (mild) 9%, 21 (moderate) 15% 21 ; myalgia (mild) 9%, 21 (moderate) 6% 21 ; tumor flare (mild) 6%, 21 (moderate) 9%, 21 (severe) 3%. 21 G. Pulmonary: Exacerbation of chronic obstructive airway disease (severe) 3%. 21 
